Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v10060310 http://scihub22266oqcxt.onion/10.3390/v10060310 C6024357!6024357!29875339     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2018 ; 10 (6): ä Nephropedia Template TP {{tp|p=29875339|t=2018. Development of Phage Lysins as Novel Therapeutics: A Historical Perspective |pdf=|usr=}}{{29875339}} gab.com Text Development of Phage Lysins as Novel Therapeutics: A Historical Perspective JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=29875339 #FOAvip Bacteriophage lysins and related bacteriolytic enzymes are now considered among the top antibiotic alternatives for solving the mounting resistance problem. Over the past 17 years, lysins have been widely developed against Gram-positive and recently Gram-negative pathogens, and successfully tested in a variety of animal models to demonstrate their efficacy. A lysin (CF-301) directed to methicillin resistant Staphylococcus aureus (MRSA) has effectively completed phase 1 human clinical trials, showing safety in this novel therapeutic class. To validate efficacy, CF-301 is currently the first lysin to enter phase 2 human trials to treat hospitalized patients with MRSA bacteremia or endocarditis. If successful, it could be the defining moment leading to the acceptance of lysins as an alternative to small molecule antibiotics. This article is a detailed account of events leading to the first therapeutic use and ultimate development of phage-encoded lysins as novel anti-infectives. Twit Text FOAVip Development of Phage Lysins as Novel Therapeutics: A Historical Perspective ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=29875339 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29875339 #FOAvip English Wikipedia <ref>{{Cite pmid|29875339}}</ref> Development of Phage Lysins as Novel Therapeutics: A Historical Perspective #MMPMID29875339 Fischetti VA Viruses 2018[Jun]; 10 (6): ä PMID29875339show ga Bacteriophage lysins and related bacteriolytic enzymes are now considered among the top antibiotic alternatives for solving the mounting resistance problem. Over the past 17 years, lysins have been widely developed against Gram-positive and recently Gram-negative pathogens, and successfully tested in a variety of animal models to demonstrate their efficacy. A lysin (CF-301) directed to methicillin resistant Staphylococcus aureus (MRSA) has effectively completed phase 1 human clinical trials, showing safety in this novel therapeutic class. To validate efficacy, CF-301 is currently the first lysin to enter phase 2 human trials to treat hospitalized patients with MRSA bacteremia or endocarditis. If successful, it could be the defining moment leading to the acceptance of lysins as an alternative to small molecule antibiotics. This article is a detailed account of events leading to the first therapeutic use and ultimate development of phage-encoded lysins as novel anti-infectives. äDevelopment of Phage Lysins as Novel Therapeutics: A Historical Perspe(epmc).pdf DeepDyve Pubget Overpricing